ANEB
Anebulo Pharmaceuticals Inc

171
Mkt Cap
$19.42M
Volume
1,330.00
52W High
$3.42
52W Low
$0.2999
PE Ratio
-2.37
ANEB Fundamentals
Price
$0.46
Prev Close
$0.4762
Open
$0.505
50D MA
$0.6206
Beta
0.10
Avg. Volume
4,920.76
EPS (Annual)
-$0.2509
P/B
2.38
Rev/Employee
$0.00
$37.07
Loading...
Loading...
News
all
press releases
Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2026 Financial Results and Recent Updates
Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage pharmaceutical company developing novel solutions for people suffering from acute cannabis-induced toxic effects (the Company or...
News Placeholder
More News
News Placeholder
Anebulo Pharmaceuticals Announces Intention to Voluntarily Delist from Nasdaq and Deregister with SEC
Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage pharmaceutical company developing novel solutions for people suffering from acute cannabis-induced toxic effects (the Company or...
News Placeholder
Anebulo Pharmaceuticals Announces Final Results of Tender Offer
Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage pharmaceutical company developing novel solutions for people suffering from acute cannabis-induced toxic effects (the Company or...
News Placeholder
Anebulo Pharmaceuticals Announces Preliminary Results of Tender Offer
Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage pharmaceutical company developing novel solutions for people suffering from acute cannabis-induced toxic effects (the Company or...
News Placeholder
How Is The Market Feeling About Anebulo Pharmaceuticals Inc?
read more...
News Placeholder
Anebulo Pharmaceuticals Announces Its Intent to Commence a Self Tender Offer
Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage pharmaceutical company developing novel solutions for people suffering from acute cannabis-induced toxic effects (the Company or...
News Placeholder
Anebulo Pharmaceuticals (NASDAQ:ANEB) Trading 0.8% Higher - Still a Buy?
Anebulo Pharmaceuticals (NASDAQ:ANEB) Stock Price Up 0.8% - Here's Why...
News Placeholder
Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2026 Financial Results and Recent Updates
Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage pharmaceutical company developing novel solutions for people suffering from acute cannabis-induced toxic effects (the Company or...
<
...
1
>

Compact View

Mini-Chart
Sentiment
Not available
Message Volume
Not available